Fotemustine overview

Fotemustine (diethyl 1-{1-[3-(2-chloroethyl)-3-nitrosoureido] ethyl} phosphonate) is an alkylating 1)  is a third-generation nitrosourea showing efficacy in melanoma, some haematological tumors, and gliomas.

It is characterized by elevated lipophilic properties and a low molecular weight that contribute to facilitation of its passage through the blood-brain barrier 2).
Moreover, fotemustine shows an important diffusion in neuronal cells and glia. The antitumor activity of fotemustine is related to its ability to alkylate DNA. After intravenous infusion, the plasma concentration reached the steady state in 45 minutes and the plasma concentration varied between 1 and 14 ug/mL disappearing in the blood within three hours 3).
Numerous phase II studies showed an important activity of fotemustine in high-grade gliomas, especially in glioblastoma, as first-line treatment or in recurrent disease 4).
Regarding its adverse events, the most important toxic events are thrombocytopenia, leukopenia, and anemia, while liver and kidney toxicity are moderate 5).
Fotemustine is a third-generation nitrosourea with an ideal pharmacological profile to treat primitive brain tumors showing efficacy in all types of glioma. Although no prospective and randomized studies were performed about the efficacy of fotemustine in malignant gliomas, results from numerous retrospective and prospective single-arm phase II clinical trials demonstrated its activity both as single agent and in combination with other cytotoxic drugs or new targeted drugs such as bevacizumab 6).
1) , 3) Tranchand B, Lucas C, Biron P, et al. Phase I pharmacokinetics study of high-dose fotemustine and its metabolite 2-chloroethanol in patients with high-grade gliomas. Cancer Chemotherapy and Pharmacology. 1993;32(1):46–52.
2) De Rossi A, Rossi L, Laudisi A, et al. Focus on Fotemustine. Journal of Experimental and Clinical Cancer Research. 2006;25(4):461–468.
4) Beauchesne P. Fotemustine: a third-generation nitrosourea for the treatment of recurrent malignant gliomas. Cancers. 2012;4(1):77–87.
5) Laquerriere A, Raguenez-Viotte G, Paraire M, et al. Nitrosoureas lomustine, carmustine and fotemustine induced hepatotoxic perturbations in rats: biochemical, morphological and flow cytometry studies. European Journal of Cancer. 1991;27(5):630–638.
6) Lombardi G, Farina P, Della Puppa A, Cecchin D, Pambuku A, Bellu L, Zagonel V. An Overview of Fotemustine in High-Grade Gliomas: From Single Agent to Association with Bevacizumab. Biomed Res Int. 2014;2014:698542. Epub 2014 Mar 31. Review. PubMed PMID: 24800248; PubMed Central PMCID: PMC3988896.

Una nueva esperanza para el glioblastoma: Vacquinol-1

Vacquinol-1, que se puede dar en forma de comprimido, hace que las células de glioblastoma, literalmente exploten, según investigadores del Instituto Karolinska, en Suecia.
Cuando se la administraron a ratones, el crecimiento del tumor se invirtió y se prolongó su supervivencia, según las conclusiones de su trabajo, publicadas en la revista Cell.
Los científicos del Instituto Karolinska y colegas en la Universidad de Uppsala, también en Suecia, han descubierto un mecanismo completamente nuevo para eliminar las células tumorales en el glioblastoma. Inicialmente, estos expertos expusieron las células tumorales a una amplia gama de moléculas.
Si las células cancerosas morían, la molécula se consideraba de interés para estudios posteriores, que inicialmente se realizaron con más de 200 tipos de moléculas. Después de extensos análisis, identificaron una sola molécula especialmente interesante.
Así detectaron que la molécula provocó en las células del glioblastoma una vacuolización (formación de cavidades) no controlada ((Kitambi SS, Toledo EM, Usoskin D, Wee S, Harisankar A, Svensson R, Sigmundsson K, Kalderén C, Niklasson M, Kundu S, Aranda S, Westermark B, Uhrbom L, Andäng M, Damberg P, Nelander S, Arenas E, Artursson P, Walfridsson J, Forsberg Nilsson K, Hammarström LG, Ernfors P. Vulnerability of Glioblastoma Cells to Catastrophic Vacuolization and Death Induced by a Small Molecule. Cell. 2014 Mar 18. pii: S0092-8674(14)00220-7. doi: 10.1016/j.cell.2014.02.021. [Epub ahead of print] PubMed PMID: 24656405.))

× How can I help you?
WhatsApp WhatsApp us
%d bloggers like this: